Table 1.
Baseline demographic characteristics in newly diagnosed patients with AML
| Variable | Patients (n = 380)n (%)/Median (Range)/Mean (±SD) |
|---|---|
| Age (years) | 40 (1–79) |
| Sex (male) | 244 (64·2) |
| Symptom duration (weeks) | 4 (1–52) |
| Distance from hospital (kilometres) | 580 (6–3200) |
| Proceeded to receive treatment | 109 (28·7) |
| ECOG PS at diagnosis | n = 373 |
| 0/1 | 289 (77·5) |
| 2 | 71 (19) |
| 3/4 | 13 (3·5) |
| Haemoglobin (g/l) | 77 ± 23·4 |
| White blood cell count (×109/l) | 16·3 (0·2–920) |
| Platelet count (×109/l) | 36 (2–394) |
| Cytogenetic Risk Group | n = 247 |
| Favourable | 29 (11·8) |
| t (8;21) | 24 |
| inv (16); t (16;16) | 5 |
| Intermediate | 173 (70) |
| Adverse | 45 (18·2) |
| monosomy 7 | 12 |
| del 5q; t(6;9); t(9;22) (1 each) | 3 |
| inv 3 | 2 |
| Complex karyotype | 28 |
ECOG PS, Eastern Cooperative Oncology Group performance score; SD, standard deviation.